Imaging the cancer immune environment and its response to pharmacologic intervention, part 2: The role of novel PET agents

Amir Iravani, Rodney J. Hicks

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Although 18F-FDG PET/CT is widely available and is increasingly being used to monitor response to immunotherapy and simultaneously identify immune-related adverse events, there are several challenges in interpreting the results of this investigation, especially early in the course of treatment. It also has limited utility in selecting the optimal type of immunotherapy. As knowledge about immune contexture increases, new targets that may be amenable to imaging are being defined. These exciting advances, coupled with increasingly sophisticated methods for generating radiopharmaceuticals, provide the potential for either replacing or complementing 18F-FDG PET/CT in the selection and monitoring of immunotherapy. Approaches include imaging specific characteristics of immune cell infiltrates or aspects of the tumor microenvironment that are known to be associated with suppression of the innate and adaptive immune response. Following a large body of preclinical work, promising agents that are entering into early clinical evaluation are discussed. We suggest a speculative algorithm as to how these might be used in routine practice, subject to validation in clinical trials.

Original languageEnglish
Pages (from-to)1553-1559
Number of pages7
JournalJournal of Nuclear Medicine
Volume61
Issue number11
DOIs
StatePublished - Nov 1 2020

Keywords

  • Immune checkpoint
  • Molecular imaging
  • Oncology: Melanoma
  • PET
  • Radiopharmaceuticals

Fingerprint

Dive into the research topics of 'Imaging the cancer immune environment and its response to pharmacologic intervention, part 2: The role of novel PET agents'. Together they form a unique fingerprint.

Cite this